Full text

Turn on search term navigation

© 2020. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Since tumor-specific T cells were first utilized to treat melanoma patients in 1986 [1], immune cell-based therapy for cancer treatment has been a topic of continuous immunological research and development, despite ups and downs in the broader interest in the subject. CARs can then be delivered into immune cells (most commonly Natural Killer (NK) or T cells) using viral vectors or other gene delivery techniques, resulting in a living drug that can seek and destroy cancer cells. Following sensational results in clinical trials over the last decade, the United States Food and Drug Administration (FDA) has so far approved three CD19-targeted CAR therapies for patients with B-cell hematological malignancies, such as lymphoma and leukemia [4]. CAR Toxicity Even though the CAR therapies show dramatic efficacy for relapsed B-cell family cancers, cytokine release syndrome (CRS) and neurotoxicity remain significant medical challenges with these therapies [8,9].

Details

Title
Current Advances and Hurdles in Chimeric Antigen Receptor Technology
First page
3329
Publication year
2020
Publication date
2020
Publisher
MDPI AG
e-ISSN
20726694
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2460858107
Copyright
© 2020. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.